Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
J. venom. anim. toxins incl. trop. dis ; 13(2): 431-445, 2007. tab
Article Dans Anglais | LILACS | ID: lil-452840

Résumé

The intestinal microbiota consists of a qualitatively and quantitatively diverse range of microorganisms dynamically interacting with the host. It is remarkably stable with regard to the presence of microorganisms and their roles which, however, can be altered due to pathological conditions, diet composition, gastrointestinal disturbances and/or drug ingestion. The present review aimed at contributing to the discussion about changes in the intestinal microbiota due to HIV-1 infection, focusing on the triad infection-microbiota-nutrition as factors that promote intestinal bacterial imbalance. Intestinal microbiota alterations can be due to the HIV-1 infection as a primary factor or the pharmacotherapy employed, or they can be one of the consequences of the disease.


Sujets)
Humains , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Infections à VIH/complications , Intestins/microbiologie , État nutritionnel
2.
J. venom. anim. toxins incl. trop. dis ; 11(2): 143-159, May-Aug. 2005. tab
Article Dans Anglais | LILACS | ID: lil-402362

Résumé

Highly active antiretroviral therapy (HAART) has been associated with the development of a clinical group and metabolic disorders such as peripheral lipodystrophy syndrome in AIDS. The aim of this study was to analyse the lipid profile, the clinical aspects, and the body composition of HIV-1 infected individuals treated with or without protease inhibitor (PI) during the highly active antiretroviral therapy. In total, 62 individuals were evaluated in this study; 15 healthy individuals (Control Group; CG), 11 HIV-1 infected individuals treated without antiretroviral therapy (Group 1: G1), 14 HIV-1 infected individuals treated with antiretroviral therapy plus protease inhibitor (Group 2: G2), and 11 HIV-1 infected individuals treated with antiretroviral therapy without protease inhibitor (Group 3: G3), mean age 35 years old. The time interval for G2 and G3 was greater than or equal to nine months. Patients receiving HAART with PI had significantly lower viral loads, hypertriglyceridemia, and low HDL levels (p<0.05). There were no differences between groups in relation to the lean body mass percentage obtained by mid-arm muscle circumference adequacy or by bioelectrical impedance. The lower percentage of body fat observed in all the HIV-1 infected patients by antropometric assessment and the decreased tricipital skinfold adequacy in the group treated with PI in relation to CG may suggest lipodystrophy in the upper limbs, especially on those treated with PI


Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Composition corporelle , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Lipides/physiologie , Retroviridae , Syndrome d'immunodéficience acquise/physiopathologie , Syndrome d'immunodéficience acquise/thérapie
SÉLECTION CITATIONS
Détails de la recherche